Rebecca Corrow, APRN
Adult Health · Mankato, MNNPI 1598116865
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 47 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 8.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $298, more than ten times the $18 reported in 2021.
Across 47 payments — averaging $17.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$71
- Jazz Pharmaceuticals Inc.$42
- Radius Health, Inc.$40
- Abiomed$40
- Travere Therapeutics, Inc.$38
- Merck$36
- plus $535 from 24 others
What the payments were for
- Food & beverage$803100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 5 | $71 |
| Jazz Pharmaceuticals Inc. | 3 | $42 |
| Radius Health, Inc. | 2 | $40 |
| Abiomed | 1 | $40 |
| Travere Therapeutics, Inc. | 1 | $38 |
| Merck | 2 | $36 |
| Exact Sciences | 2 | $34 |
| Calliditas Therapeutics US Inc. | 2 | $34 |
| Phathom Pharmaceuticals, Inc. | 2 | $33 |
| GSK | 2 | $33 |
| Aimmune Therapeutics, Inc. | 2 | $32 |
| Dexcom, Inc. | 2 | $31 |
| Aurinia Pharma U.S., Inc. | 2 | $30 |
| Philips North America LLC | 2 | $28 |
| Medtronic | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Electromed, Inc. | 2 | $22 |
| Ardelyx, Inc. | 1 | $22 |
| Novartis | 1 | $20 |
| Bayer | 1 | $18 |
| AbbVie | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Rhythm Pharmaceuticals, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| Pfizer | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| AstraZeneca | 1 | $15 |
| Lundbeck LLC | 1 | $15 |
| Corium, LLC | 1 | $11 |
How this compares
$803 in reported general payments places this provider in the 85th percentile of 233 adult health providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 65 | $74,016 |
| EliquisApixaban | 50 | $44,783 |
| XareltoRivaroxaban | 31 | $43,933 |
| OzempicSemaglutide | 23 | $38,076 |
| RexultiBrexpiprazole | 14 | $20,576 |
| LinzessLinaclotide | 25 | $18,586 |
| RybelsusSemaglutide | 11 | $16,225 |
| JardianceEmpagliflozin | 11 | $15,168 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 11 | $14,827 |
| TrulicityDulaglutide | 13 | $14,499 |
| MyrbetriqMirabegron | 18 | $13,295 |
| JanuviaSitagliptin Phosphate | 16 | $12,708 |
| FarxigaDapagliflozin Propanediol | 17 | $10,900 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 13 | $9,550 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 24 | $8,010 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $16 | $88,51578 claims |
| PfizerEliquis | $15 | $44,78350 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $15 | $20,57614 claims |
| AbbVieLinzess, Synthroid | $18 | $20,16846 claims |
| AstraZenecaFarxiga, Symbicort | $15 | $14,82532 claims |
| MerckJanuvia | $36 | $12,70816 claims |
| GSKAnoro Ellipta | $33 | $7,84411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 233 adult health providers in Minnesota.
Other adult health in Mankato
- Sarah JaxSt Louis Park$86K
- Marcus BurnsMinneapolis$51K
- William SharpMinneapolis$37K
- Brian GoodroadMinneapolis$29K
- Alicia WojchikChaska$14K
- Kelli DalyEdina$11K
- Bridget FlynnMinneapolis$7K
- Devon EllenaApple Valley$7K
- Maureen VantineMinneapolis$6K
- Margaret LongleySaint Paul$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.